Potential Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- AF recurrence
研究概览
简要总结
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital on AF patients with structural heart disease. Eplerenone 25 mg daily will be given and searching for AF recurrence among study population.
详细描述
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital, on 100 patients with AF and structural heart disease. AF is confirmed by electrocardiography. The patients were divided into 2 groups:
Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Group B (control group): 50 patients received amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with non-valvular AF who underwent cardioversion to sinus rhythm either medical, electrical or even spontaneously
排除标准
- •Patients with rheumatic heart disease.
- •Thyroid dysfunction.
- •Wolf-Parkinson-White (WPW) syndrome.
- •Renal impairment.
- •Hyperkalemia.
- •Acute coronary syndrome.
- •Pregnancy.
- •Left ventricular (LV) dysfunction with ejection fraction (EF) less than 40%.
- •On current use of eplerenone.
研究组 & 干预措施
Study arm
Were given Eplereone 25 mg daily
干预措施: Eplereone (Drug)
Control arm
Were given nothing
干预措施: Eplereone (Drug)
结局指标
主要结局
AF recurrence
时间窗: 6 months
次要结局
未报告次要终点
研究者
Ahmed Abdelgaleel
Professor
Assiut University